Cargando…
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344720/ https://www.ncbi.nlm.nih.gov/pubmed/37457127 http://dx.doi.org/10.20517/cdr.2022.146 |
_version_ | 1785072921355485184 |
---|---|
author | Bouberhan, Sara Bar-Peled, Liron Matoba, Yusuke Mazina, Varvara Philp, Lauren Rueda, Bo R. |
author_facet | Bouberhan, Sara Bar-Peled, Liron Matoba, Yusuke Mazina, Varvara Philp, Lauren Rueda, Bo R. |
author_sort | Bouberhan, Sara |
collection | PubMed |
description | Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or short-lived. Over the last several years, multiple new classes of agents targeting DNA damage response (DDR) mechanisms have advanced through clinical development. In this review, we explore the preclinical rationale for the use of ATR inhibitors, CHK1 inhibitors, and WEE1 inhibitors, emphasizing their application to chemotherapy-resistant and PARPi-resistant ovarian cancer. We also present an overview of the clinical development of the leading drugs in each of these classes, emphasizing the rationale for monotherapy and combination therapy approaches. |
format | Online Article Text |
id | pubmed-10344720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103447202023-07-15 The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer Bouberhan, Sara Bar-Peled, Liron Matoba, Yusuke Mazina, Varvara Philp, Lauren Rueda, Bo R. Cancer Drug Resist Review Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or short-lived. Over the last several years, multiple new classes of agents targeting DNA damage response (DDR) mechanisms have advanced through clinical development. In this review, we explore the preclinical rationale for the use of ATR inhibitors, CHK1 inhibitors, and WEE1 inhibitors, emphasizing their application to chemotherapy-resistant and PARPi-resistant ovarian cancer. We also present an overview of the clinical development of the leading drugs in each of these classes, emphasizing the rationale for monotherapy and combination therapy approaches. OAE Publishing Inc. 2023-06-14 /pmc/articles/PMC10344720/ /pubmed/37457127 http://dx.doi.org/10.20517/cdr.2022.146 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Bouberhan, Sara Bar-Peled, Liron Matoba, Yusuke Mazina, Varvara Philp, Lauren Rueda, Bo R. The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title | The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title_full | The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title_fullStr | The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title_full_unstemmed | The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title_short | The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer |
title_sort | evolving role of dna damage response in overcoming therapeutic resistance in ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344720/ https://www.ncbi.nlm.nih.gov/pubmed/37457127 http://dx.doi.org/10.20517/cdr.2022.146 |
work_keys_str_mv | AT bouberhansara theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT barpeledliron theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT matobayusuke theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT mazinavarvara theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT philplauren theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT ruedabor theevolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT bouberhansara evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT barpeledliron evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT matobayusuke evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT mazinavarvara evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT philplauren evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer AT ruedabor evolvingroleofdnadamageresponseinovercomingtherapeuticresistanceinovariancancer |